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TO THE EDITOR
In recent months, IL36RN has been
investigated in various inflammatory
conditions. IL36RN variants are com-
mon in generalized pustular psoriasis
(GPP) (Setta-Kaffetzi et al., 2013)
without plaque psoriasis (Sugiura et al.,
2013) and acrodermatitis continua of
Hallopeau (Setta-Kaffetzi et al., 2013),
and somewhat rarer in acute genera-
lized exanthematous pustulosis (Navarini
et al., 2013) and palmoplantar pustulosis
(Setta-Kaffetzi et al., 2013). They do
not predispose to plaque psoriasis
(Berki et al., 2013). Sugiura et al. (2013)
describe the early age of onset, genera-
lized pustular eruptions in IL36RN
compound heterozygote twins, initially
triggered by amoxicillin, which then
became recurrent. While infection is
reported to trigger pustular eruptions in
GPP, given the positive patch test, the
drug seems the more likely candidate.
Whether such cases should be diag-
nosed as acute generalized exanthema-
tous pustulosis or drug-elicited GPP
remains a matter of expert opinion at
present in the absence of a gold standard
for separating these two entities, and for
RegiSCAR, case ascertainment (Navarini
et al., 2013) comprised a scoring system
involving clinical and histological criteria
and formal board review. However,
Sugiura’s cases raise the intriguing
possibility that IL36RN provides the
mechanistic link between the two, and
supports the notion that the disease
taxonomy of pustular eruptions (in
general) might be better served when
based on pathogenic mechanisms and
genetic profiling.
Concerning Sugiura et al.’s suggestion
of avoiding amoxicillin administration to
known patients with clinically manifest
DITRA (deficiency of the IL-36 receptor
antagonist): we believe that the evidence
from the three compound heterozygous/
homozygous cases (Navarini et al.,
2013; Sugiura et al., 2013) alone is not
sufficient to postulate such a general
recommendation. However, we suggest
that for these patients, collecting data
with patch testing for b-lactam anti-
biotics is worthwhile both on clinical
and scientific grounds. Given the rarity
of the condition, this could be addressed
in dedicated networks such as the newly
formed European Rare and Severe
Psoriasis Expert Network (ERASPEN).
Sugiura et al. (2013) also suggest
avoiding administration of amoxicillin
or penicillin-related drugs to carriers of
variants in IL36RN. The value of pre-
treatment genetic testing is established
for only a limited number of drugs, most
notably certain HLA risk alleles that
predict risk of severe cutaneous adve-
rse drug reactions, for example: HLA-B*
57:01 HIV before administration of
abacavir (Martin et al., 2012), as 6%
are otherwise affected by hypersen-
sitivity. However, IL36RN variants are
rare, thus the number needed to test
would be high, greatly limiting the
clinical utility of such a strategy. In
addition, although it seems clear that
amoxicillin was the trigger of the
pustular eruption in the cases reported,
it does not automatically follow that all
patients with IL36RN variants will react
similarly, or that the avoidance of
amoxicillin would have prevented the
subsequent manifestation of GPP. This
might have to be demonstrated before
adopting such a testing strategy for
general use.
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TO THE EDITOR
When scanning the newly published
literature cited on PubMed/Medline, it
is almost a weekly occurrence that I
see something go by stating that the
skin is the largest organ in the human
body. The problem is that there is no
factual basis for this ubiquitous dog-
matic statement.
As an example, the editor’s introduc-
tion to the timely and informative
Review Series on Dermatology that
appeared in the 1 February 2012 issue
(volume 122, issue 2) of the Journal of
Clinical Investigation began with the
following sentence ‘‘Though the body’s
largest organ, the skin may be occasion-
ally forgotten as a site of clinically
important disease.’’ Similar statements
have been made in earlier Journal of
Investigative Dermatology publications
authored by prominent dermatology/
skin biology investigators (Setoguchi
et al., 1994; Bickers and Athar, 2006;
Clark et al., 2007).
On 31 May 2013, a PubMed search
using the phrase, ‘‘skin largest organ’’
returned 194 citations. A review of the
text of the abstracts accompanying the
first 20 of those citations revealed that in
16 (80%) it was specifically stated that
the skin is the largest human organ.
However, published data simply do
not support the ‘‘common knowledge’’
proposition that the skin is the largest
organ in the human body.
An earlier analysis of this question by
Goldsmith (1990) eloquently and humo-
rously concluded that the human skin is
not the largest organ in the human body.
By weight, the skin may be considered to
be the largest of the ‘‘medium-sized’’
organs such as the liver and brain. How-
ever, the skin is no match in weight for the
much larger organs of the musculoskeletal
system. In such comparisons, clearly the
musculoskeletal system must be consi-
dered as a human organ system.
Goldsmith’s (1990) assumptions and
calculations resulted in a determination
that the human skin (epidermis plus
dermis) weighs 3.86 kg, or 5.5% of the
total body weight of the proverbial
70 kg man.
It has been reported that the skeleton
accounts for B14% of the human
body’s weight (Reynolds, 1977). In
addition, it has been reported that an
average adult male is made up of 42%
of skeletal muscle and an average adult
female is made up of 36% (as a
percentage of body mass; Marieb and
Hoehn, 2007).
If one included the subcutaneous fat,
the skin by mass would be a stronger
contender for being the largest organ in
the human body. However, as its name
implies ‘‘subcutaneous’’ fat is not an
official part of the skin. Wikipedia also
states that human skin is the largest
organ. However, Wikipedia, that fount
of conventional wisdom, also states that
the skin is composed of the epidermis
and dermis. It specifies that the hypo-
dermis (subcutaneous tissue) under-
lies the skin but is not part of the skin
(http://en.wikipedia.org/wiki/Skin#Hypo
dermis/, accessed 31 May 2013).
Nor can the skin be considered to be
the largest human organ with respect to
functional surface area. The human
skin surface area is identical to body
surface area. The body surface area
of the proverbial 70 kg man is 1.7 m2
(Goldsmith, 1990). By comparison, the
gas exchanging surface of the lung’sAccepted article preview online 7 August 2013; published online 12 September 2013
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